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This issue contains different aspects of the broad spectrum
of clinical psychiatry.
In the paper by Schaub et al. [1], the interplay between
psychopathological syndromes and psychosocial function-
ing in chronic schizophrenia is examined. This is of special
importance facing a continuous discussion what our treat-
ment options mean to real life functioning for the patients.
On the other hand, it is important to analyse whether
psychopathological abnormalities revealed in patients are
as important for the patients as to the examiner.
Suffering from schizophrenia means to a substantial
proportion of the patients to take antipsychotic agents for a
signiﬁcant proportion of their lifetime, leading to side
effects like the metabolic syndrome. Therefore, it is
important to have reliable data on the prevalence and
clinical correlates of it in patients suffering from schizo-
phrenia as documented by Barbosa et al. [2]. However, not
only patients with schizophrenia suffer from the metabolic
consequences of long-term pharmacotherapy but also
patients with acute depression face similar problems as was
outlined by Richter et al. [3]. Along these lines, it should be
stressed that the pharmacogenetics of antidepressant treat-
ment will in the near future not only give support in the
choice of the right substance looking at the efﬁcacy but
furthermore taking the special side effect proﬁle into
account [4]. Along these lines, the paper by Illi et al. [5]
analyses the connection between 5-HTTLPR and selective
serotonin reuptake inhibitors in major depression. Finally
concluding this complex, the interest is drawn to a paper by
Kikuchi et al. [6] performing an internet survey on patients’
attitude towards side effects of antidepressant treatment.
Linking state-of-the-art electrophysiology with person-
ality traits, Mittermeier et al. [7] examined the role of audi-
tory-evoked potentials in an emotional choice reaction task
in relation to personality traits measured by the NEO FFI.
Researching the proteome in major psychiatric illnesses
beyond schizophrenia or depression (as laid out in [8]), a
recent study analysing the human amygdala found an
impact of tubulin on drug-abusing behaviour [9]. In an
article in this issue examining the consequences of alcohol
abuse, Wedekind et al. [10] analysed S100B and homo-
cysteine in the acute alcohol withdrawal syndrome. These
and other neurobiological ﬁndings seem to deﬁne sub-
groups of patients with addictive behaviour pointing to the
necessity of individualised treatments in alcohol depen-
dents [11].
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